Suppr超能文献

发现一对非对映异构体作为有效的组蛋白去乙酰化酶(HDACs)抑制剂:绝对构型的确定、生物活性比较及计算研究。

Discovery of a Pair of Diastereomers as Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study.

作者信息

Zhang Yingjie, Inks Elizabeth S, Zhu Mengyuan, Chou C James, Fang Hao, Li Minyong, Shen Yuemao, Yi Fan, Xu Wenfang

机构信息

Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong, 250012, P. R. China.

出版信息

RSC Adv. 2013 Nov 21;3(43). doi: 10.1039/C3RA43249A.

Abstract

Histone deacetylase inhibitors (HDACi) are still the focus of epigenetic modulator development due to their effective intervention in many pathological processes. In our previous research, a potent HDACi was designed, synthesized and validated as a promising antitumor candidate named ZYJ-34c. Enlarged scale synthesis of ZYJ-34c for further detailed research was hindered by the occurrence of a by-product, which was identified as an isomer of ZYJ-34c by HRMS and H NMR. Subsequent synthesis route modification and optimization revealed that these two isomers were a pair of epimers and their absolute configurations could be directly determined by our optimized synthesis routes, through which each optically pure epimer could be stereoselectively synthesized, respectively. Based on these results, we concluded that our previously reported absolute configuration of ZYJ-34c was incorrect. It is worth noting that the epimer of ZYJ-34c exhibited more potent HDACs inhibition and both in vitro and in vivo antitumor activities, and moreover, their different HDACs inhibitory activities could be rationalized by computational simulations of their binding modes in HDAC2.

摘要

组蛋白去乙酰化酶抑制剂(HDACi)因其对许多病理过程的有效干预,仍然是表观遗传调节剂开发的焦点。在我们之前的研究中,设计、合成并验证了一种有效的HDACi,它是一种名为ZYJ-34c的有前景的抗肿瘤候选物。由于一种副产物的出现,阻碍了ZYJ-34c的扩大规模合成以进行进一步的详细研究,通过高分辨质谱(HRMS)和氢核磁共振(H NMR)鉴定该副产物为ZYJ-34c的一种异构体。随后的合成路线修改和优化表明,这两种异构体是一对差向异构体,并且它们的绝对构型可以通过我们优化的合成路线直接确定,通过该路线可以分别立体选择性地合成每种光学纯的差向异构体。基于这些结果,我们得出结论,我们之前报道的ZYJ-34c的绝对构型是错误的。值得注意的是,ZYJ-34c的差向异构体表现出更强的组蛋白去乙酰化酶(HDACs)抑制作用以及体外和体内抗肿瘤活性,此外,它们不同的HDACs抑制活性可以通过其在HDAC2中的结合模式的计算模拟来解释。

相似文献

8
Design and synthesis of novel histone deacetylase 6 inhibitors with benzyl-triazole as the core skeleton.
Biosci Trends. 2019 Jul 22;13(3):267-272. doi: 10.5582/bst.2019.01054. Epub 2019 May 31.
9
Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Clin Epigenetics. 2018 Jul 31;10(1):100. doi: 10.1186/s13148-018-0531-y.

引用本文的文献

1
Many-molecule encapsulation by an icosahedral shell.
Elife. 2016 May 11;5:e14078. doi: 10.7554/eLife.14078.

本文引用的文献

3
Developing histone deacetylase inhibitors as anti-cancer therapeutics.
Curr Med Chem. 2011;18(11):1658-71. doi: 10.2174/092986711795471284.
5
Epigenetic opportunities and challenges in cancer.
Drug Discov Today. 2010 Jan;15(1-2):65-70. doi: 10.1016/j.drudis.2009.10.010. Epub 2009 Nov 6.
6
An operational definition of epigenetics.
Genes Dev. 2009 Apr 1;23(7):781-3. doi: 10.1101/gad.1787609.
7
Epigenetic regulation in psychiatric disorders.
Nat Rev Neurosci. 2007 May;8(5):355-67. doi: 10.1038/nrn2132.
8
The epigenomics of cancer.
Cell. 2007 Feb 23;128(4):683-92. doi: 10.1016/j.cell.2007.01.029.
9
Histone deacetylase: a regulator of transcription.
Science. 1996 Apr 19;272(5260):371-2. doi: 10.1126/science.272.5260.371.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验